Entering into application on January 31, 2022 alongside the Clinical Trials Information System (CTIS), Regulation (EU) No 536/2014 mandates that clinical trial sponsors publish plain-language Layperson Summaries in the official languages of all participating EU Member States.
Harmonizing Multi-Country Trial Submissions Through CTIS
On January 31, 2022, the European Union Clinical Trials Regulation (Regulation EU No 536/2014) officially entered into application, replacing the legacy Clinical Trials Directive (2001/20/EC). At the heart of the reform is the centralized Clinical Trials Information System (CTIS) managed by the European Medicines Agency (EMA). Under the new regime, pharmaceutical sponsors can submit a single clinical trial application across up to 30 EEA countries simultaneously, subject to strict 12-day Request for Information (RFI) response turnarounds that demand agile, pre-aligned multilingual translation workflows.
Annex V Plain-Language Summaries and Health Literacy
A landmark transparency requirement under Article 37 and Annex V of the CTR is that within 12 months of a trial's conclusion (6 months for pediatric trials), sponsors must submit a Summary of Clinical Trial Results written in plain language understandable to laypersons. in accordance with EU Good Lay Summary Practice (GLSP), these summaries must be translated into the official national languages of every EU Member State where the trial was conducted, avoiding medical jargon while preserving scientific accuracy.
Executive Takeaways for Global Enterprises
- Key Insight: Regulation (EU) No 536/2014 and the EMA CTIS portal go live on January 31, 2022, centralizing EU clinical trial authorizations.
- Key Insight: Tight 12-day regulatory RFI windows require rapid, ISO 17100-certified medical translation workflows.
- Key Insight: Annex V mandates plain-language Layperson Summaries translated into all participating Member State languages.
Nota Editorial y de Referencia: Este análisis técnico ha sido elaborado de forma independiente por el equipo de investigación de Alphatrad Worldwide con fines de análisis profesional y cumplimiento normativo. Para la documentación oficial y las fuentes primarias, consulte:
Fuente Oficial y Referencia: European Medicines Agency (EMA) & EUR-Lex (Regulation EU 536/2014) (https://www.ema.europa.eu/en/human-regulatory-overview/clinical-trials-human-medicines)
¿Necesita traducciones multilingües certificadas, juradas o localización conforme a las normas ISO para sus proyectos internacionales? Solicite un presupuesto personalizado gratuito a Alphatrad y reciba un plan de entrega detallado en un plazo de 24 horas.